Spotlight: Apr-Jun 2022

Words by Cheyenne Eugene

GOLD looks back at some of the top news stories from the pharmaceutical industry over the last few months, ranging from recent drug approvals to exciting new initiatives and much more


12 April

Draft guidance puts Pfizer and Shionogi’s antibiotics in the UK’s new antimicrobial financing model


16 April

‘Our Africa by Merck Foundation’ TV programme launches to raise awareness of health issues on the continent


26 April

PatientView survey shows improved corporate reputation for pharma among patient groups


17 May

MHRA approves Roche’s Vabysmo eye injection as treatment option for two leading forms of sight loss


25 May

Pfizer launches not-for-profit equity initiative to provide medicines to 45 lower-income countries


28 May

FDA grants accelerated approval for Novartis’ Kymriah for adult patients with relapsed or refractory follicular lymphoma


30 May

NRG Therapeutics wins £2.68m award to develop new treatments for neurodegenerative disorders


31 May

Sandoz launches ‘Act4Biosimilars’ initiative to improve patient access in over 30 countries by 2030


01 June

Pascal Soriot, CEO, AstraZeneca, awarded knighthood for services to UK life sciences and leadership during COVID-19


02 June

Regeneron buys exclusive license rights to Sanofi’s cancer treatment Libtayo for $900m


03 June

BMS announces acquisition of leading precision oncology company Turning Point Therapeutics


06 June

FDA approves GSK’s Priorix for the prevention of measles, mumps and rubella in those 12 months and older


This article features in GOLD 22 – read the full issue here.